Last reviewed · How we verify
NCT05301465
Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.
trial in Gastric Cancer Stage IV in 50 participants. Status unknown.
1 November 2022
Quick facts
| Lead sponsor | University of Pisa |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 November 2021 |
| Primary completion | 1 November 2022 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across Italy |
Conditions studied
- Gastric Cancer Stage IV — all drugs for Gastric Cancer Stage IV →
Sponsor
University of Pisa
Who can join
18 and older, any sex, with Gastric Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The project is primarily aimed at identifying and subsequently validating the predictive role of plasma concentrations of VEGF-A (vascular endothelial growth factor A), VEGF-D (vascular endothelial growth factor D) and s-VEGFR2 (soluble Vascular Endothelial Growth Factor Receptor 2) measured prior to initiation and during second-line treatment with paclitaxel and ramucirumab in patients with unresectable gastric cancer pretreated with first-line chemotherapy. For the primary endpoint, the efficacy parameter chosen is PFS, calculated from day 1 of treatment to date of progression or death.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.
Fornaro L, Musettini G, Orlandi P, Pecora I, et al · · 2022 · cited 7× · PMID 35968330
Verify or expand the search:
- PubMed search for NCT05301465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer Stage IV
Currently open trials in the same condition.
- NCT05319639 — Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab · Phase 1, PHASE2 · recruiting
- NCT04592211 — Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer · Phase 1, PHASE2 · recruiting
Other University of Pisa trials
Trials by the same sponsor.
- NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
- NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
- NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
- NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05301465 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pisa
- Last refreshed: 29 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05301465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing